Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children

被引：0

作者：

Yara Dadalti Fragoso

Tarso Adoni

Joseph B. Bidin Brooks

Alessandro Finkelsztejn

Paulo Diniz da Gama

Anderson K. Grzesiuk

Vanessa Daccach Marques

Monica Fiuza K. Parolin

Henry K. Sato

Daniel Lima Varela

Claudia Cristina F. Vasconcelos

机构：

[1] Universidade Metropolitana de Santos,

[2] Hospital Sirio-Libanes de Sao Paulo,undefined

[3] Hospital de Clinicas de Porto Alegre,undefined

[4] Pontificia Universidade Católica Campus Sorocaba,undefined

[5] Neurologic Clinic in Cuiaba,undefined

[6] Universidade de Sao Paulo Campus Ribeirao Preto,undefined

[7] Neurologic Clinic in Curitiba,undefined

[8] Instituto de Neurologia de Curitiba,undefined

[9] Servico de Neurologia e Neurocirurgia,undefined

[10] Universidade Federal do Estado do Rio de Janeiro,undefined

来源：

Neurology and Therapy | 2018年 / 7卷

关键词：

Family planning; Multiple sclerosis; Neurology; Pregnancy; Therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Multiple sclerosis (MS) management presently aims to reach a state of no (or minimal) evidence of disease activity. The development and commercialization of new drugs has led to a renewed interest in family planning, since patients with MS may face a future with reduced (or no) disease-related neurological disability. The advice of neurologists is often sought by patients who want to have children and need to know more about disease control at conception and during pregnancy and the puerperium. When MS is well controlled, the simple withdrawal of drugs for patients who intend to conceive is not an option. On the other hand, not all treatments presently recommended for MS are considered safe during conception, pregnancy and/or breastfeeding. The objective of the present study was to summarize the practical and evidence-based recommendations for family planning when our patients (women and men) have MS.

引用

页码：207 / 232

页数：25

共 495 条

[111] Callaway LK(2016)Multiple sclerosis disease-modifying therapy and pregnancy Mult Scler 2014 513160-26
[112] Dahl J(2001)Risk-benefit assessment of glatiramer acetate in multiple sclerosis Drug Saf 45 187-138
[113] Myhr KM(2010)Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 114 616-509
[114] Daltveit AK(2014)Multiple sclerosis and pregnancy: current considerations Sci World J 41 1660-107
[115] Chen YH(2004)Successful pregnancy after cladribine therapy for hairy cell leukemia Leuk Lymphoma 32 269-1407
[116] Lin HL(2009)Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol 28 89-205
[117] Lin HC(2007)Fingolimod: a novel immunosuppressant for multiple sclerosis Ann Pharmacother 82 674-35
[118] Mueller BA(2018)Efficacy and safety of the newer multiple sclerosis drugs approved since 2010 CNS Drugs 10 125-2676
[119] Zhang J(2014)A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis CNS Drugs 2016 1034912-1253
[120] Critchlow CW(2014)Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis Neurology 8 233-413

← 7 8 9 10 11 12 13 14 15 16 →